Finance

Beta
Lists
HAE:NYSE
Haemonetics Corp
$71.43
+2.31%
(+1.61) 1D
Jun 5, 3:59:47โ€ฏPM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HAE...
Open
$70.10
High
$71.66
Low
$69.64
Mkt. cap
3.24B
Avg. vol.
933.64K
Volume
377.90K
P/E ratio
34.76
52-wk high
$87.32
52-wk low
$47.32
EPS
$2.05
Beta
0.56
Shares outstanding
45.45M
No. of employees
3K
Open
$70.10
High
$71.66
Low
$69.64
Mkt. cap
3.24B
Avg. vol.
933.64K
Volume
377.90K
P/E ratio
34.76
52-wk high
$87.32
52-wk low
$47.32
EPS
$2.05
Beta
0.56
Shares outstanding
45.45M
No. of employees
3K
Analyst outlook
Analyst Ratings
Based on 8 analysts giving stock ratings to HAE in the past 3 months
Buy
Buy
5
Hold
3
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for HAE in the last 3 months.
Highest
Current $71.43
$89.00 (+24.60%)
Average
$74.57 (+4.40%)
Lowest
$62.00 (-13.20%)
News stories
From sources across the web
Profile
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen Latham in the 1970s. Today, the company has expanded and has offices located in 16 countries. The company employs more than 1,800 people and markets its products in over 50 countries. Revenue is derived nearly equally from its three major markets -- Asia, Europe, and the Americas. Wikipedia
About Haemonetics Corp
CEOChristopher Simon
Employees3.01K
Founded1971
HeadquartersBoston, Massachusetts, United States
SectorMedical device
Websitehaemonetics.com
Last report
May 7, 2026
Fiscal period
Q4 2026
EPS / Est. (USD)
$1.29 / $1.27
+1.38%beat
Revenue / Est. (USD)
346.35M / 336.84M
+2.82%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
321.39M
327.32M
338.97M
346.35M
Cost of goods sold
129.54M
132.71M
136.63M
148.10M
Cost of revenue
129.54M
132.71M
136.63M
148.10M
Research and development expenses
15.58M
14.52M
14.29M
14.41M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
99.95M
100.10M
105.90M
125.29M
Operating expense
126.92M
125.80M
131.12M
150.19M
Total operating expenses
256.46M
258.52M
267.75M
298.28M
Operating income
64.94M
68.80M
71.22M
48.07M
Other non operating income
-
-7.21M
2.28M
-21.16M
EBT including unusual items
45.17M
51.28M
59.98M
-28.40M
EBT excluding unusual items
56.24M
61.59M
63.79M
37.79M
Income tax expense
11.14M
12.60M
15.24M
-8.25M
Effective tax rate
24.66%
24.57%
25.40%
29.06%
Other operating expenses
-
-
-
-
Net income
34.03M
38.68M
44.74M
-20.15M
Net profit margin
10.59%
11.82%
13.20%
-5.82%
Earnings per share
1.10
1.27
1.31
1.29
Interest and investment income
-
-
-
10.10M
Interest expense
-4.07M
-
-9.70M
-
Net interest expenses
-4.07M
-
-9.70M
10.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
93.70M
97.05M
98.60M
69.28M
Gain or loss from assets sale
-243.00K
-75.00K
-218.00K
-178.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer